RecruitingPHASE1, PHASE2NCT03167437
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
Studying Chronic granulomatous disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Ivan J Fuss, M.D.National Institute of Allergy and Infectious Diseases (NIAID)
- Intervention
- Vorinostat(drug)
- Enrollment
- 35 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2017 – 2026
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03167437 on ClinicalTrials.govOther trials for Chronic granulomatous disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07284641Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)Paul Szabolcs
- ENROLLING BY INVITATIONPHASE1NCT07113743Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous DiseaseNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGPHASE1, PHASE2NCT06876363Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous DiseaseEnsoma
- RECRUITINGNCT06605378Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous DiseaseEnsoma
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT06559176A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )Prime Medicine, Inc.
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT06253507pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD)National Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGPHASE1NCT06325709Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous DiseaseNational Institute of Allergy and Infectious Diseases (NIAID)
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT05600907Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)National Institute of Allergy and Infectious Diseases (NIAID)